Contact: [email protected]
Title | Tumor type | Line | Study information |
---|---|---|---|
Regina | Rectal | Neoadjuvant | Regorafenib + nivolumab + short course RT in intermediate risk stage II-III |
AZUR-2 | CRC | Neoadjuvant | Rand. study of perioperative Dostarlimab mono vs. SOC (surgery + adj chemo) in T4N0 or Stage III dMMR/MSI-H resectable CRC |
IMCODE003 (GO44479) | Pancreas | Adjuvant | Autogen cevumeran IV + atezo + mFOLFIRINOX vs. mFOLFIRINOX; screening before surgery |
Fortitude101 (20210096) | Gastric | 1L | Bemarituzumab vs. placebo + FOLFOX6 in FGFR2b positive disease (IHC) |
Destiny04 | Gastric | 2L | Trastuzumab deruxtecan vs. paclitaxel-ramucirumab in HER2+ (IHC 3+/2+) disease |
Fortitude102 (20210098) | Gastric | 1L | Bermarituzumab vss placebo + Nivolumab + mFOLFOX6 in FGFR2b positive disease (IHC) |
Nalpac | Pancreas | 2L | Naliri vs Nalirinox. PD after 1st line gemcitabine mono or gem/abraxane |
RGX202-002 | CRC | 2L | Ompenaclid vs. placebo + FOLFIRI+bevacizumab in RAS mutant CRC |
Stereopac | Pancreas | Neoadjuvant | preop mFOLFIRINOX (or gem/NabP) +/- SBRT in borderline resectable |
Mountaineer-03 (SGNTUC-029) | CRC | 1L | Tucatinib+trastuzumab + mFOLFOX6 vs. mFOLFOX6 +/- bevacizumab/cetuximab in HER2+, RAS wt CRC |
Imbrave152 | HCC | 1L | Tiragolumab (anit-TIGIT) vs. placebo + atezolizumab + bevacizumab |
REPLACE (TRIO 041) | HCC | 1L | Regorafenib + pembrolizumab vs. TACE or TARE |